How many drugs treat Infantile autism?

Drug Landscape tracks 4 marketed treatments for Infantile autism (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infantile-autism.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infantile autism — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infantile autism (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infantile autism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Abilify	aripiprazole	Generic (originally Otsuka/BMS)	Third-generation antipsychotic (D2 partial agonist)	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	2002-11-15
Risperdal	risperidone	Johnson & Johnson (Janssen)	Atypical Antipsychotic [EPC]	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	1993-12-29
Abilify	Abilify	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Risperdal	Risperdal	Ohio State University		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Otsuka/BMS) · 1 drug in Infantile autism
Johnson & Johnson (Janssen) · 1 drug in Infantile autism
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in Infantile autism
Ohio State University · 1 drug in Infantile autism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infantile autism:

Cite this brief

Drug Landscape (2026). Infantile autism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infantile-autism. Accessed 2026-06-10.

Infantile autism full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing